Q-omics provides the consensus-scored C20orf204 profile across patient tissues and cancer cell-line models. C20orf204 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, C20orf204 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, C20orf204 RNA expression shows 17,297 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KIRC, and UVM as cancer lineages where C20orf204 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C20orf204 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C20orf204 survival associations across molecular data types. C20orf204 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C20orf204 RNA expression–survival associations across cancer types. High C20orf204 expression shows unfavorable associations in ACC, KIRC, COAD, KIRP and UVM, but favorable associations in HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for C20orf204 RNA expression.
This table summarizes C20orf204 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for C20orf204. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C20orf204 shows higher tumor expression in KIRC, HNSC, COAD, BLCA, LIHC and STAD. The KIRC box plot shows higher C20orf204 RNA expression in tumor versus normal tissue (log2 FC = +0.228, t-test p < 0.001).
This table shows molecular features associated with C20orf204 in patient tissues and cancer cell lines. In patient samples, C20orf204 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, C20orf204 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE.
